CHRSCoherus Oncology, Inc.

$226M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M-40.8% YoY

Gross Profit

$20M37.5% margin

Operating Income

-$42M-78.0% margin

Net Income

-$51M-93.6% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-23.5%

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$29M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$449M

Total Liabilities

$581M

Stockholders' Equity

-$132M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$92M	-40.8%
Gross Profit	$20M	$7M	+191.6%
Operating Income	-$42M	-$69M	+38.7%
Net Income	-$51M	-$80M	+36.4%

Revenue Segments

Product

$189M96%

Product and Service, Other

$7M4%

CHRS Q4 2024 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena